<DOC>
	<DOCNO>NCT01447472</DOCNO>
	<brief_summary>The purpose study : 1. evaluate involvement CYP2D6 , CYP3A4 CYP1A2 ( dextromethorphan caffeine challenge ) , catechol-O-methyltransferase ( COMT ) MDMA metabolism 2. evaluate gender difference human pharmacology MDMA 3. study influence genetic polymorphism ( CYP2D6 , COMT , SERT ) effect pharmacokinetics MDMA .</brief_summary>
	<brief_title>-Methylenedioxymethamphetamine ( MDMA , Ecstasy ) Induced Changes Drug Metabolism : Gender Genetic Polymorphisms</brief_title>
	<detailed_description />
	<mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Healthy male female adult , recreational use MDMA least ten occasion ( two previous year ) , EM phenotype CYP2D6 activity determine use dextromethorphan selective probe drug . Women present regular menstrual cycle take oral contraceptive . Daily consumption &gt; 20 cigarette &gt; 4 standard unit ethanol men ( &gt; 2 woman ) Regular ingestion medication month precede study Presence major psychiatric disorder History abuse drug dependence ( except nicotine dependence ) Psychiatric adverse reaction MDMA consumption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>MDMA ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>CYP2D6 , COMT ,</keyword>
	<keyword>SERT , 5-HTTLPR , gender ,</keyword>
	<keyword>dextromethorphan ,</keyword>
	<keyword>caffeine .</keyword>
</DOC>